Skip to main content
KWANGDONG PHARMACEUTICAL CO.,LTD logo

KWANGDONG PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 009290 ISIN · KR7009290008 KO Manufacturing
Open in API
Filings indexed 280 across all filing types
Latest filing 2025-10-28 Capital/Financing Update
Country KR South Korea
Listing KO 009290

About KWANGDONG PHARMACEUTICAL CO.,LTD

https://eng.ekdp.com/

Kwangdong Pharmaceutical is a human healthcare company that develops, manufactures, and sells a diverse range of products, including pharmaceuticals and health-oriented beverages. Founded on the principle of the 'scientification of Oriental medicine,' the company integrates traditional Korean medicinal concepts with modern Western science. Its portfolio includes Over-the-Counter (OTC) and prescription (ETC) drugs, general health supplements, and traditional health foods. The company is also prominent in the consumer market with its popular beverage lines, featuring well-known products such as the Vita 500 vitamin drink and Corn Silk Tea. Additionally, Kwangdong is involved in the distribution of mineral water.

Recent filings

Filing Released Lang Actions
[기재정정]주요사항보고서(교환사채권발행결정)
Capital/Financing Update Classification · 95% confidence The document is a Korean regulatory filing titled '주요사항보고서(교환사채권 발행결정)' which translates to 'Material Information Report (Exchangeable Bond Issuance Decision)'. It details the cancellation of a previously decided issuance of exchangeable bonds and mentions alternative financing plans through a capital increase. The document is a formal announcement to the financial authorities (Financial Services Commission and Korea Exchange) about the cancellation of a bond issuance decision. It does not contain financial statements or detailed financial analysis but is a notification of a capital/financing update event. The document length is about 2975 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2025-10-28 Korean
[기재정정]주요사항보고서(자기주식처분결정)
Transaction in Own Shares Classification · 95% confidence The document is a '주요사항보고서(자기주식 처분 결정)' which translates to a 'Material Fact Report (Decision on Disposal of Treasury Shares)'. It includes details about the decision to dispose of treasury shares, the cancellation of a convertible bond issuance, and plans for capital increase through affiliated companies. The document is addressed to the Financial Services Commission and Korea Exchange, indicating it is a regulatory disclosure. The content focuses on share disposal decisions and related corrections, not on financial results, management changes, or meeting materials. The document length is 2743 characters, which is relatively short and typical for a regulatory announcement. This fits the category of Transaction in Own Shares (POS), which covers reports of the company buying back or selling its own shares. Therefore, the appropriate classification is POS with high confidence.
2025-10-28 Korean
[정정명령부과]주요사항보고서(교환사채권발행결정)
Capital/Financing Update Classification · 95% confidence The document is a detailed disclosure about the decision to issue exchangeable bonds (교환사채권 발행결정) by 광동제약주식회사. It includes specifics about the bond issuance such as amount, terms, interest rate, maturity, conversion price adjustments, put options, and the purpose of the funds raised. It also contains financial data of related companies and explanations about the rationale for the issuance and its impact on shareholders. The document is a regulatory disclosure related to capital raising through exchangeable bonds, which fits the category of Capital/Financing Update (CAP). It is not an annual or interim report, audit report, or earnings release. It is not a simple announcement of a report but a substantive disclosure about financing activity. Therefore, the correct classification is CAP with high confidence.
2025-10-20 Korean
[정정명령부과]주요사항보고서(자기주식처분결정)
Capital/Financing Update Classification · 95% confidence The document is a detailed disclosure regarding the decision to dispose of treasury shares (자기주식 처분 결정) by the company 광동제약주식회사. It includes specifics about the number of shares, pricing, disposal method, purpose, and related financial details. The document references the issuance of exchangeable bonds (교환사채) with treasury shares as the exchange target, and it provides extensive information on the rationale, impact on shareholders, and financial conditions related to this transaction. This type of detailed disclosure about treasury share disposal and related financing activities fits the category of Capital/Financing Update (CAP). It is not an announcement of a report publication, nor is it a full financial report or earnings release. It is a regulatory disclosure about a significant capital transaction involving treasury shares and exchangeable bonds.
2025-10-20 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is titled '주식등의 대량보유상황보고서(일반)' which translates to 'Report on Large Shareholding Status (General)'. It contains detailed information about the number of shares held, shareholding ratios, changes in shareholding, contracts related to shares, and information about the major shareholder and related parties. The document references the Capital Market and Financial Investment Business Act and includes data on shareholding changes, contracts, and voting rights. There is no indication that this is an announcement of a report publication or a certification. The content is a detailed report on major shareholding notifications, consistent with filings required when significant share ownership thresholds are crossed or when there are changes in major shareholdings. Therefore, the document fits the category of 'Major Shareholding Notification' (MRQ).
2025-10-14 Korean
자기주식처분결과보고서
Transaction in Own Shares Classification · 100% confidence The document is titled '자기주식처분결과보고서' which translates to 'Report on Disposal of Treasury Shares'. It details the disposal of treasury shares by the company 광동제약주식회사, including dates, quantities, prices, and counterparties. The document is a formal report submitted to the financial supervisory authority (금융감독원장 귀하) and includes specific transaction details of the company's own shares. This matches the description of a 'Transaction in Own Shares' filing, which reports on the company's buyback or sale of its own shares. The document length is 2222 characters, which is consistent with a detailed transaction report rather than a brief announcement or a full financial report. Therefore, the correct classification is POS (Transaction in Own Shares).
2025-10-01 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.